Nirmatrelvir and Ritonavir [PAXLOVID]

Patent oppositions filed in
Argentina, Colombia, India, and Viet Nam

An antiviral combination medicine comprising Nirmatrelvir and Ritonavir for use in the treatment of Covid-19 infection.

This drug is missing the following documents, can you help us by contributing something?


Information related to relevant oppositions from around the world.

Patent Oppositions

The table includes oppositions aimed at contesting patents covering this drug. Note that at the country level, several patent applications can cover the same drug.

Please pay attention not only to the patent opposition, but also to the patent application it relates to, see column "Related Patent Application". To better identify similarities, the column "Patent Type" indicates a general classification of the patent. Arguments used to contest a specific type of patent may apply for another that fits in the same category.

CountryDateWho FiledOpposition typeOpposition statusPatent typeRelated patent applicationMore info
Colombia12-06-2022Grupo de Investigación Plebio-Universidad Nacional de Colombia-UNAL. JDR, FHT, Oscar Lizarazo. UAEM-UNAL-Colombia; Centro de Pensamiento, Medicamentos-UNAL and OthersPre-GrantUnder ExaminationMoleculesPCT/IB2021/057281 WO/2021/250648 View/Comment
Viet Nam14-03-2023Vietnam National Network of People Living with HIV/AIDS (VNP+)Pre-GrantUnder ExaminationMoleculesVN1-2021-07603 / WO/2021/250648View/Comment
India15-12-2023Sankalp Rehabilitation TrustPre-GrantUnder ExaminationMolecules202117051620View/Comment
Argentina27-12-2022Fundación Grupo Efecto PositivoPre-GrantUnder ExaminationMoleculesAR123111A1View/Comment

Is something missing? Help us by contributing missing data: Contribute

↑ Back to Top